October 23, 2015 5:04pm

 

Don't be gulled into any high-risk pricing as the sector gyrates because there are the lack of actionable news from which to base decisions. Sentiment needs to be regenerated for more than one day.

Any buys made here are fundamentally a short in the dark. Subscription required: http://www.regmedinvestors.com/user/register , read more …

 

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

U.S. equities closed sharply higher Friday after the Chinese central bank cut interest rates and after three tech giants posted better-than-expected earnings.

The NASDAQ closed UP +111.81 or +2.27% to 5,031.86 and the DOW closed UP +157.54 or +0.90% to 17,646.70.

 

 

Henry’omics:

  • The SCGT&RM sector open to the upside on a Friday, a new first <for the week> and stayed … positive at the close!

The sector’s recovered <Friday, even before a weekend> from an oversold condition of the past week. This is an extremely short-term observation, which doesn’t say that sentiment is identified with the green screen.

  • That oversold condition was very actionable and acted as a buy signal, and the stem, cell and gene therapy RegMed sector appropriately bounced back from that exaggerated condition, but subsequently it justifies an irrational market.

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed UP on Friday +10.17 or +3.32% following Thursday’s +1.65 or +0.54% after Wednesday’s decline of -9.98 or -3.16% on Tuesday following Monday’s advance of +1.62 or +0.52%;
  • The NASDAQ Biotechnology index (NBI) closed UP on Friday +91.69 or +2.86% following Thursday’s +189.14 or +0.57% on Thursday after Wednesday’s decline of -1.50 or -0.49% following Tuesday’s decline of -106.24 or -3.21% after Monday’s advance of +18.62 or +0.57%;
  • The Russell 2000 (IWM) closed UP 1.13 or +0.99% on Friday following Thursday’s +1.00 or +0.88% after Wednesday’s decline of -1.74 or -1.51% after Tuesday’s -0.16 or -0.14% following Monday’s advance of +0.22 or +0.19%;
  • The SPDR SD&P Biotech ETF (XBI) closed UP +1.50 or +2.34% on Friday following Thursday’s decline of -0.14 or -0.22% after Wednesday’s decline of -0.09 or -0.14% following Tuesday’s decline of -2.25 or -3.38% after Monday’s advance of +0.51 or +0.77%

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • The SCGT & RM equities opened positive with an A/DL of 31/8 and 3 flats staying but slipping to a positive second hour with an A/DL of 28/13 and 2 flats to sojourn at a positive mid-day A/DL of 29/12 and 2 flats;
  • The closing bell synched positive to end the session with an A/DL of 29/12 and 2 flats.

Volume is still low in respect to today’s uplift versus the past day’s downdraft!

  • My fear index, the CBOE Volatility Index (VIX) traded Friday near 14 after Thursday’s near 15 following Wednesday’s above 16 in contrast to Tuesday’s and Monday’s near 15.

The sector’s venue: “Veniremus, emimus, vendidit” – the new mantra, we came, we bought, we sold!  

 

 

Dosing the sector – what a day for the 43 Patients:

  • Open: POSITIVE with 8 decliners, 31 advances and 3 flats;
  • Mid-day (1 pm): POSITIVE with 12 decliners, 29 advancers and 2 flats;
  • Closing bell: POSITIVE with 12 decliners, 29 advancers and 2 flats

 

 

Friday’s trading indications – 7 hits/ 3 miss:

  • Applied Genetic Technologies (AGTC) closed DOWN -$0.04 – miss;
  • Bellicum Pharma (BLCM) closed UP- hit;
  • Blue bird bio (BLUE) closed UP – hit;
  • Capricor (CAPR) closed DOWN -$0.23 – hit;
  • Intrexon (XON) closed UP – hit;
  • Juno Therapeutics (JUNO) closed UP – miss;
  • Kite Pharma (KITE) closed UP – hit;
  • MiMedx (MDXG) closed UP – hit;
  • Sangamo Biosciences (SGMO) closed UP – hit;
  • Spark Therapeutics (ONCE) closed UP – miss;

 

 

Who was down – top 5:

  • Regenxbio (RGNX) closed down -$1.00 to $14.15;
  • VistaGen (VSTA) -$0.75 to $7.00;
  • Verastem (VSTM) -$0.13 to $1.81;
  • Capricor (CAPR) -$0.23 to $3.95;
  • BioLife Solutions (BLFS) closed down -$0.09 to $2.20

 

 

Who was UP:

  • Bluebird bio (BLUE) closed up +$6.73 to $83.10;
  • Spark Therapeutics (ONCE) +$2.85 to $61.81;
  • Kite Pharma (KITE) +$2.80 to $70.61;
  • Intrexon (XON) +$1.95 to $32.93;
  • Juno Therapeutics (JUNO) +1.82 to $49.22;

 

 

Who is flat?

  • ReNeuron (RENE.L) at $3.875;
  • Stemline (STML) at $8.60;

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.